NCT04013542View on ClinicalTrials.gov

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
ALK Gene RearrangementEGFR Gene MutationLocally Advanced Lung Non-Small Cell CarcinomaLung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Unresectable Lung Non-Small Cell Carcinoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04013542 - Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | Biotech Hunter | Biotech Hunter